CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 / PRNewswire / – Harbor BioMed (HKEX: 02142) today announced that it has entered into a multi-year, multi-faceted research collaboration agreement with the Dana-Farber Cancer Institute to co-develop novel biotherapies in the treatment of cancer.
Scientists at Harbor BioMed and researchers at Dana-Farber will work together to develop new oncology drugs, including bispecific antibodies and CAR-T cell products. In recent years, both bispecific antibodies and CAR-T cell therapies are regarded as the next generation solutions in the field of tumor immunology. For their ability to engage two different targets, bispecific antibodies are expected to expand the therapeutic possibilities of monoclonal antibodies (mAbs), and CAR-T cell therapy is an innovative immunotherapy that uses specially modified T cells to redirect them to target cancer cells. .
This strategic collaboration will leverage Harbor BioMed’s Harbor Mice® transgenic platform with Dana-Farber’s expertise in CAR-T cell development and basic oncology research to generate novel biotherapies.
Harbor BioMed’s antibody technology platforms – Souris Harbor®, which is based on two proprietary transgenic mouse platforms, will be used to generate therapeutic human antibodies. The platforms have great potential to generate both conventional and next-generation biologics, such as bi- and multi-specific, CAR-T or VH domain derivatives that are fully human, matured by affinity with excellent solubility and developability.
“We are delighted to initiate this collaboration with Harbor BioMed. The complementary technology and expertise between Harbor and DFCI will dramatically shorten the time between a new discovery and the development of optimized antibodies and cell therapies for clinical translation, ”said Dr. Eric smith, Laboratory Principal investigator and director of translational research for immune effector cell therapies at the Dana-Farber Cancer Institute.
“Collaboration with the world-renowned Dana-Farber Cancer Institute demonstrates HBM’s commitment to developing new drugs and fostering innovative, accelerated research. I believe this collaboration will ultimately result in better treatments for cancer patients, ”said Jingsong Wang, founder, CEO of HBM.
About the Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a teaching hospital in Harvard Medical School. Dana-Farber is committed to providing cancer patients with the best possible care today, while advancing the treatments of tomorrow through intensive basic and clinical research. We are a leader in developing national cancer treatment guidelines and in improving the quality and effectiveness of cancer care. Our unique model of multidisciplinary, compassionate and collaborative care puts patients and their families at the center of everything we do. Our areas of expertise include breast cancer, skin cancer, gynecological cancers, lung cancer, stem cell transplants and cancer clinical trials.
About Harbor BioMed
Harbor BioMed (HKEX: 02142) is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic antibodies focused on oncology and immunology. The Company builds its solid portfolio and differentiated pipeline through internal R&D capabilities, collaborations with co-discovery and co-development partners and selected acquisitions.
Harbor Mice’s proprietary antibody technology platforms® generate fully human monoclonal antibodies in the two heavy chain and two light chain format (H2L2), as well as the heavy chain only format (HCAb). Based on anti-HCAb antibodies, HCAb-based immune cell activators (HBICE ™) are capable of producing tumor-killing effects not achievable by traditional combination therapies. Integrating Harbor Mice® with a unique B cell cloning platform, our antibody discovery engine is very unique and efficient for the development of next generation therapeutic antibodies.
For more information, please visit www.harbourbiomed.com
SOURCE Port BioMed